PacBio Files 8-K on Financial Results and Exhibits

TL;DR

**PacBio just filed an 8-K about their financial results and statements, but the actual numbers aren't in this snippet.**

AI Summary

Pacific Biosciences of California, Inc. filed an 8-K on February 15, 2024, to report on its results of operations and financial condition. The filing also indicated the furnishing of financial statements and exhibits. This specific excerpt does not detail the actual financial performance or specific dollar amounts, focusing instead on the nature of the disclosure.

Why It Matters

This 8-K signals that Pacific Biosciences is providing updated financial information to the public, which is crucial for investors to assess the company's performance and make informed decisions. It indicates transparency and compliance with SEC regulations.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure for reporting financial results and exhibits, and the provided text does not indicate any unusual or negative events.

Key Players & Entities

• PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — registrant
• February 15, 2024 (date) — date of report
• Delaware (location) — state of incorporation
• Menlo Park, California (location) — principal executive offices

FAQ

From the Filing

0001299130-24-000014.txt : 20240215 0001299130-24-000014.hdr.sgml : 20240215 20240215160728 ACCESSION NUMBER: 0001299130-24-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240215 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 24643844 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 pacb-20240215.htm 8-K pacb-20240215 0001299130 false 0001299130 2024-02-15 2024-02-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 15, 2024 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 15, 2024, Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its fourth fiscal quarter and year ended December 31, 2023. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference. This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securit